PTC Therapeutics, Inc. Deferred Revenue (Non-Current)
PTC Therapeutics, Inc. (PTCT) had Deferred Revenue (Non-Current) of $9.30 million as of 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Balance Sheet › Liabilities › Deferred Revenue, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2018-05-09
- 2018-03-31: Deferred Revenue, Noncurrent $9.30M.
- 2017-12-31: Deferred Revenue, Noncurrent $7.95M.
- 2017-09-30: Deferred Revenue, Noncurrent $6.58M.
- 2017-06-30: Deferred Revenue, Noncurrent $3.83M.
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2018-03-31 | $9.30M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $7.95M 10-Q · filed 2018-05-09 |
| 2017-09-30 | $6.58M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $3.83M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $2.19M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $1.59M 10-K · filed 2018-03-06 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-16 |
| 2013-06-30 | $241.67K 10-Q · filed 2013-08-13 |
| 2012-12-31 | $741.67K 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |